ANDA 75-737 March 15, 2002

Clay-Park Labs, Inc.
Attention: Candis Edwards
1700 Bathgate Ave.
Bronx, NY 10457

Dear Madam:

This is in reference to your abbreviated new drug application dated November 18, 1999, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act (Act), for Minoxidil Topical Solution USP, 5% (For Men).

Reference is also made to your amendments dated September 6, and December 6, 2001.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted Over-The-Counter (OTC) labeling. Accordingly the application is approved. The Division of Bioequivalence has determined your Minoxidil Topical Solution USP, 5% (For Men) to be bioequivalent to the listed drug (Rogaine® Extra Strength, 5% (For Men) of Pharmacia & Upjohn Co.).

Under Section 506A of the Act, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Sincerely yours,

Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research

cc: ANDA 75-737
Division File
Field Copy
HFD-610/R. West
HFD-210/B. Poole
HFD-330
HFD-205

Endorsements:
HFD-623/N.Takiar/
HFD-623/D.Gill/
HFD-617/R.Wu
HFD-613/L.Golson/
HFD-613/J.Grace/

V:\FIRMSAM\CLAYPARK\LTRS&REV\75737.AP.doc

F/T by: DJ 3/6/02

APPROVAL